UK Stem Cell Bank - Third Phase

2002年，英国政府建立了一个人类胚胎细胞系银行，以监督这些细胞的使用，以确保在英国使用的任何这种类型的细胞都是合乎道德地获得的，并且仅用于治疗严重人类疾病的研究。此外，世行应提供这些细胞系的质量控制库存，以提供高质量的国际资源，支持英国S干细胞界，并进一步将这些细胞用于再生医学。世界银行在支持干细胞疗法从实验室转移到床边方面的这种作用被确认为约翰·帕蒂森爵士编写并得到政府接受的英国干细胞倡议报告中的一个关键要素。在下一阶段的供资(第三阶段)中，世行的目标是维持和发展其作为符合国际质量标准的人类干细胞系库存的最重要的储存库的地位，这些储存库是合乎道德的和特点良好的。虽然在第二阶段，世行的主要重点是学术研究，但在第三阶段，世行将与将研究发展转化为治疗应用的科学计划、再生医学临床社区以及那些开发人类细胞培养模型的计划进行更密切的协调，以提高新药开发的效率，以降低成本和提高患者安全。世行将继续发挥其在支持干细胞治疗发展方面的国际作用，方法是：？提供质量保证和安全测试的细胞系和其他支持研究人员和临床应用的产品；？在最佳做法和为提供高质量和安全的干细胞制定国际共识标准方面继续发挥领导作用；？正在制定干细胞科学家、技术人员和质量保证人员的培训计划，以支持英国S发展再生医学产业；它的科学合作和内部研究计划建立了强大的细胞扩增、分化、保存和鉴定方法，这将提高研究材料的供应质量，并为临床应用提供改进的方法方法。

In 2002 the UK Government established that a Bank of human embryonic cell lines should be established to oversee the use of these cells to ensure that any cells of this type, used in the UK were obtained ethically and only used in research for the benefit of treatment of serious human disease. In addition the Bank should provide access to quality-controlled stocks of these cell lines to provide a high quality international resource in support of the UK s stem cell community and to further the use of these cells in regenerative medicine. Such a role for the Bank in supporting the move of stem cell therapies from the laboratory to the bedside was confirmed to be a key element in the UK Stem Cell Initiative Report prepepared by Sir John Pattison and accepted by the Government. In the next phase of funding (Phase III) the Bank aims to sustain and develop its position as the foremost repository of ethically-sourced and well characterised stocks of human stem cell lines banked to international quality standards. Whilst in Phase II the primary focus of the Bank was on academic research, Phase III will see the Bank coordinating more closely with scientific programmes translating research developments into therapeutic applications, the regenerative medicine clinical community and those developing human cell culture models to improve the efficiency of development of new drugs to reduce costs and increase patient safety. The Bank will continue to develop its international role in supporting the development of stem cell therapy through:? the provision of quality-assured and safety tested cell lines and other products supporting researchers and clinical applications;? its continued lead on best practice and the setting of international consensus standards for the delivery of high quality and safe stem cells;? its developing training programme for stem cell scientists, technical staff and quality assurance personnel in support of the UK s developing regenerative medicine industry;? its scientific collaborations and internal research programme to establish robust methodologies for cell expansion, differentiation, preservation and characterisation which will improve the qulity of materials supplied for research and provide improved methodological approaches for clincial application.It is intended that the Bank will now implement its position as a national resource and international centre of expertise in support of the development of regenerative medicines and product safety in the UK.